Katerina Prokopiou, ARVO 2022: Stargardt disease and dry age-related macular degeneration: omega-3 fatty acids supplementation
Stargardt disease is a rare genetic eye disease that happens when fatty material builds up on the macula. An overview of the rationale for the use of omega-3 fatty acids in patients with Stargardt disease and dry age-related macular degeneration are discussed in this touchOPHTHALMOLOGY interview with Dr Katerina Prokopiou (University of Nicosia Medical School, Engomi, Cyprus) as well as the unmet needs of therapeutic interventions in patients with vision loss due to retinal degeneration.
The presentation entitled ‘A prospective, multicentre, randomised, double-blind study designed to assess the potential effects of omega-3 fatty acids supplementation in dry age-related macular degeneration or Stargardt disease’ was presented at the The Association for Research in Vision and Ophthalmology, May 01-04, 2022
- What are the challenges and unmet needs of therapeutic interventions in patients with vision loss due to retinal degeneration?
- What is the rationale for the use of omega-3 fatty acids in patients with dry age-related macular degeneration or Stargardt disease?
Disclosures: Katerina Prokopiou has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the virtual ARVO 2022.
Share this Video
Related Videos In Macular Degeneration
Jordana Fein, ARVO 2023: Phase II CANDELA study post hoc analysis: intravitreal aflibercept injection 8 mg versus 2 mg
The CANDELA trial (NCT04126317) was a phase II, randomized, single-masked, open-label, clinical trial that assessed the safety and efficacy of aflibercept 8 mg versus the standard dose of 2 mg in patients with neovascular age-related macular degeneration (nAMD). It was a pleasure to speak with Dr Jordana Fein (Retina Group of Washington Fairfax, VA, USA) […]
Jordana Fein, ARVO 2023: Current therapeutic options for neovascular age-related macular degeneration
Neovascular age-related macular degeneration (nAMD) is an advanced form of macular degeneration that historically has accounted for the majority of vision loss related to AMD. Current treatment consists of injecting inhibitors of vascular endothelial growth factor (VEGF) into the vitreous cavity to interfere with proliferation of choroidal neovascularization and to reduce vascular permeability. It was […]
Dilsher Dhoot, AAO 2022: Sustained-release axitinib hydrogel implant in wet AMD, phase 1 results
A sustained-release axitinib hydrogel implant poses advantages for the treatment of wet age-related macular degeneration (wet AMD). In this touchOPHTHALMOLOGY interview, we speak with Dr Dilsher Dhoot (California Retina Consultants, Santa Barbara, CA, USA) to discuss the phase 1 study of the axitinib hydrogel implant, its findings and the next steps for its development. The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!